[Comment] Multiple standards of care in non-small-cell lung cancer after EGFR-TKI therapy: progress, fragmentation, or inevitability?

This comment examines the progress, fragmentation, and inevitability of multiple standards of care in EGFR-mutated non-small-cell lung cancer after EGFR-TKI therapy. The global MARIPOSA-2 trial showed that amivantamab plus platinum-pemetrexed chemotherapy improved PFS over platinum-pemetrexed chemotherapy alone in patients progressing after osimertinib, and it became the preferred second-line option in NCCN and ESMO guidelines.